BBRX: Braeburn Pharmaceuticals, Inc. - Summary | Jitta

Braeburn Pharmaceuticals, Inc.

NASDAQ:BBRX

Notice
Stock data is unavailable or the company’s delisted.
Price
n/a
Loss Chance
58.4%
1.95JITTA SCORE
n/a
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Related
Sorry, the data is not yet available for this stock.
Jitta Factors
Growth Opportunity (10)
Recent Business Performance (35)
Financial Strength (0)
Return to Shareholders (10)
Competitive Advantage (0)
Jitta Signs
Key Stats
Jitta Score
Jitta Line
1.95
n/a
3.05
180.63%
COMPANY DESCRIPTION
Braeburn Pharmaceuticals, Inc. develops and commercializes medications for serious disorders of the central nervous system. Its lead therapeutic area is opioid addiction, a chronic relapsing brain disease characterized by long-lasting structural and functional changes in the brain. The company offers product candidates, including weekly and monthly CAM2038, that are subcutaneous injectable formulations of buprenorphine for the treatment of opioid addiction. The company was formerly known as AT Pharmaceuticals, Inc. and changed its name to Braeburn Pharmaceuticals, Inc. in December 2012. The company was founded in 2012 and is headquartered in Plymouth Meeting, Pennsylvania.